- Medical Malpractice
- Product
- Unsafe Drugs
- Pradaxa
- Metal-on-Metal Hip Implant Litigation
- Hip Implants - DePuy ASR Hip Recall
- Hip Implants - Zimmer Durom Cup Hip Recall
- Vaginal Mesh Litigation
- Vaginal Mesh - Bard Avaulta Surgical Mesh
- Accutane
- Actos
- Avandia
- Bisphosphonate Litigation
- Chantix
- Darvon and Darvocet Recall
- Knee Implant - Zimmer NexGen CR-Flex
- Kugel Hernia Mesh Patches
- Mentor ObTape Vaginal Sling
- Ortho Evra Birth Control Patch
- Yasmin, Yaz, and Ocella Birth Control
- Other/Archive Drug Products
- Personal Injuries
- Auto Accidents
- Nursing Home Abuse
Public Health Advisory Issued on Psoriasis Drug Raptiva
On February 19, 2009, the FDA issued a public health advisory for patients using the psoriasis drug Raptiva concerning three confirmed and one possible report of a rare but extremely serious brain infection called progressive multifocal leukoencephalopathy (PML) that has been linked to long-term use of the drug. Raptiva was approved by the FDA in 2003.The drug is administered weekly by injection to those suffering from moderate to severe plaque psoriasis. Raptiva works by suppressing the immune system to reduce psoriasis flare-ups, however by suppressing the body's natural defense system, it can also increase the risk of serious infections and malignancies in patients. In the Fall of 2009, the drug received a “black box warning” for potential risk of developing life-threatening infections. The FDA is continuing to monitor adverse events associated with Raptiva and strongly recommends that health care professionals carefully monitor patients using Raptiva (as well as those who have discontinued the drug) for any signs or symptoms of neurologic disease.
Click here to view the FDA public health advisory on Raptiva